US1101221083
© BusinessWire
26.11.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Citi’s 2025 Global Healthcare Conference on Thursday, December 4, 2025.
The company will take part in a fireside chat beginning at 9:00 a.m. ET.
Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archiv...
Themefolio
Profiler
Peergroup
© BusinessWire
24.11.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic th...
Themefolio
Profiler
Peergroup
© BusinessWire
24.11.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Host Hematology-Focused Investor Event
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that, following the conclusion of the American Society of Hematology (ASH) Annual Meeting and Exposition, the company will hold a virtual investor event on Thursday, December 11, 2025, to highlight key Hematology programs.
The company will host a webcast beginning at 9:00 a.m. ET, which is accessib...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
18.11.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
News Preview
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb”), today announced the accepted amounts and pricing terms of the previously announced tender offers to purchase for cash its outstanding notes listed in the tables below.
The outstanding debt securities listed in (i) the first table below labeled “Pool 1” are referred to collectivel...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
18.11.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
News Preview
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb”), today announced the early participation results, as of 5:00 p.m. (New York City time) on November 17, 2025, (the “Early Tender Deadline”) of the previously announced tender offers to purchase for cash its outstanding notes listed in the tables below. Bristol Myers Squibb also annou...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2025
BMY
LISTED
NYSE
Update on Phase 3 Librexia ACS Trial
News Preview
Bristol Myers Squibb (NYSE:BMY) in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS) event. The decision to disco...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that it has priced a public offering (the “Offering”) of senior unsecured notes in a combined aggregate principal amount of €5 billion (collectively, the “Notes”). The Notes will be issued by Bristol Myers Squibb’s wholly-owned subsidiary, BMS Ireland Capital Funding Designated Activity Company, in...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data from its cardiovascular portfolio at the American Heart Association’s Scientific Sessions 2025, taking place November 7–10, 2025 in New Orleans, Louisiana. New analyses include results from a long-term extension study and real-world evidence that reinforce how Camzyos (mavac...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
News Preview
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb” or the “Offeror”), announced the commencement of tender offers (“Offers”) to purchase for cash certain of its outstanding notes (collectively, the “Notes”) as described in the tables below.
Pool 1
Offers to purchase for cash up to $4,000,000,000 aggregate purchase price for the sec...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today reported third quarter 2025 financial results.
Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed third quarter 2025 earnings press release and investor presentation.
The company will host a conference call and live audio webcast for analysts and investors at 8:...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
News Preview
Bristol Myers Squibb (NYSE:BMY) today announced Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial further confirming the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) who were not previously treated with a biologic disease-modifying antirheumatic drug (bDMARD). The company also announced ne...
Themefolio
Profiler
Peergroup
© BusinessWire
25.10.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced updated data and first disclosure of results in chronic, refractory autoimmune diseases from the Phase 1 Breakfree-1 study (NCT05869955) of its investigational, autologous CD19-targeted NEX-T™ CAR T cell therapy BMS-986353 (CC-97540). The data, evaluating a total of 71 treated patients across the sy...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
17.10.2025
BMY
LISTED
NYSE
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
News Preview
REDMOND, Wash. and PRINCETON, N.J., Oct. 17, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from the global phase I US-Lung-101 study (NCT0...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2025 to be held from October 17-21 in Berlin, Germany. Data from more than 50 company-sponsored studies, investigator-sponsored studies, and collaborations showcase result...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
BMY
LISTED
NYSE
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
News Preview
REDMOND, Wash., Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negativ...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
News Preview
Bristol Myers Squibb (NYSE: BMY, “BMS”) and Orbital Therapeutics (“Orbital”) today announced a definitive agreement under which BMS will acquire Orbital, a privately held biotechnology company pioneering a new generation of RNA medicines that reprogram the immune system in vivo, enabling treatments that provide the precision, control, and flexibil...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2025
BMY
LISTED
NYSE
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the launch of its COBENFY Connections™ initiative in partnership with culinary expert, TV host and author Gail Simmons.* Launching on World Mental Health Day, the initiative features real stories from people affected by schizophrenia, including Simmons, who shares her perspective through her brother...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
BMY
LISTED
NYSE
Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer’s disease. Fast Track Designation is intende...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its direct-to-patient offerings, providing eligible U.S. patients with steeply discounted prices for Eliquis® (apixaban) and Sotyktu® (deucravacitinib). Eligible cash-pay patients can now purchase these medicines directly from BMS and significantly lower their out-of-pocket costs....
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD™), combined with standard therapies (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma (RRMM) demonstrated a statistically significant improvement...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the call at http://inves...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
BMY
LISTED
NYSE
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
News Preview
MarketNewsUpdates News Commentary
NEW YORK, Sept. 18, 2025 /CNW/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant growth due to the rising awareness about the benefits of cell therapies. They help regenerate damaged tissues and organs. They hav...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
BMY
LISTED
NYSE
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
News Preview
MarketNewsUpdates News Commentary
NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant growth due to the rising awareness about the benefits of cell therapies. They help regenerate damaged tissues and organs. T...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
BMY
LISTED
NYSE
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
News Preview
MarketNewsUpdates News Commentary
NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant growth due to the rising awareness about the benefits of cell therapies. They help regenerate damaged tissues and organs. T...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
BMY
LISTED
NYSE
Advancing Cancer Research Brings New Hope for Patients Worldwide
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic to...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
BMY
LISTED
NYSE
Advancing Cancer Research Brings New Hope for Patients Worldwide
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic to...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
BMY
LISTED
NYSE
Advancing Cancer Research Brings New Hope for Patients Worldwide
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Sept. 17, 2025 /CNW/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic toll on y...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Dividend
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on November 3, 2025, to stockholders of record at the close of business on October 3, 2025.
In addition, the Board of Direc...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum on Tuesday, September 23, 2025.
The company will take part in a fireside chat beginning at 9:40 a.m. ET.
Investors and the general public are invited to listen to the sess...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today presented results from COLLIGO-HCM, a global retrospective real-world data study, in an oral session at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The analysis showed that Camzyos (mavacamten) was associated with reductions in left ventricular outflow tract (LVOT) obstruction and...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025.
The company will take part in a fireside chat beginning at 8:30 a.m. ET.
Investors and the general public are invited to listen to the session by visiting http://investo...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29 – September 1, 2025, in Madrid, Spain. Data to be presented at the meeting include new real-world analyses of Camzyos (mavacamten) in pa...
Themefolio
Profiler
Peergroup
© PR Newswire
18.08.2025
BMY
LISTED
NYSE
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
News Preview
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B01D1-LUNG-101 (U.S.,/EU) studiesREDMOND, Wash. and PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotec...
Themefolio
Profiler
Peergroup
© PR Newswire
04.08.2025
BMY
LISTED
NYSE
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Aug. 4, 2025 /PRNewswire/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatmen...
Themefolio
Profiler
Peergroup
© PR Newswire
04.08.2025
BMY
LISTED
NYSE
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is g...
Themefolio
Profiler
Peergroup
© PR Newswire
04.08.2025
BMY
LISTED
NYSE
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Aug. 4, 2025 /PRNewswire/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatmen...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today reported second quarter 2025 financial results.
Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed second quarter 2025 earnings press release and investor presentation.
The company will host a conference call and live audio webcast for analysts and investors at...
Themefolio
Profiler
Peergroup
© BusinessWire
28.07.2025
BMY
LISTED
NYSE
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
News Preview
Bristol Myers Squibb (NYSE: BMY, “BMS”) and Bain Capital today announced the creation of a new independent biopharmaceutical company (“NewCo”) focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launches with five immunology assets in-licensed from BMS and a $300 mi...
Themefolio
Profiler
Peergroup
© BusinessWire
25.07.2025
BMY
LISTED
NYSE
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company’s early-stage and late-stage product development across all therapeutic areas.
“We are thrilled t...
Themefolio
Profiler
Peergroup
© BusinessWire
21.07.2025
BMY
LISTED
NYSE
Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
News Preview
Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026. Th...
Themefolio
Profiler
Peergroup
© BusinessWire
18.07.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl® (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions did not meet its primary endpoint of RBC transfusion independence during a...
Themefolio
Profiler
Peergroup
© BusinessWire
17.07.2025
BMY
LISTED
NYSE
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
News Preview
The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today announced a new direct-to-patient option for purchasing Eliquis® (apixaban) via our Alliance’s patient resource Eliquis 360 Support. The offering provides an opportunity for uninsured, underinsured, or self-pay patients to significantly lower their out-of-pocket co...
Themefolio
Profiler
Peergroup
© BusinessWire
27.06.2025
BMY
LISTED
NYSE
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi® (lisocabtagene maraleucel; liso-cel) for the treatment of large B cell lymphoma (LBCL) and other lymphomas and Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of mu...
Themefolio
Profiler
Peergroup
© BusinessWire
17.06.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Dividend
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2025, to stockholders of record at the close of business on July 3, 2025.
In addition, the Board of Directors...
Themefolio
Profiler
Peergroup
© BusinessWire
16.06.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of the primary analysis results of the marginal zone lymphoma (MZL) cohort of TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory disease. The new data will b...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new data from its targeted protein degradation platform during the 2025 European Hematology Association (EHA) Annual Congress being held from June 12-15 in Milan, Italy. Presentations feature updated clinical findings on the company’s investigational oral CELMoD™ agents mezigdomi...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2025 on Thursday, July 31, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the call at http://investo...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
News Preview
Bristol Myers Squibb (NYSE:BMY) today announced positive data from the pivotal Phase 3 POETYK PsA-1 trial (IM011-054) evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) who were not previously treated with a biologic disease-modifying antirheumatic drug (bDMARD). The trial met its primar...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
BMY
LISTED
NYSE
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
News Preview
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work joint...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025.
The company will take part in a fireside chat beginning at 10:00 a.m. ET.
Investors and the general public are invited to listen to the session by visiting http://investor...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved a new Opdivo® (nivolumab) formulation associated with a new route of administration (subcutaneous use [SC]), a new pharmaceutical form (solution for injection) and a new strength (600 mg/vial). Opdivo SC, or nivolumab for subcutaneous use co-formulated...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May 30-June 3 in Chicago, Illinois. Data from more than 80 company-sponsored studies, investigator-sponsored studies, and collaborations showcase re...
Themefolio
Profiler
Peergroup
© BusinessWire
21.05.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Bernstein 41st Annual Strategic Decisions Conference on Wednesday, May 28, 2025.
The company will take part in a fireside chat beginning at 3:30 p.m. ET.
Investors and the general public are invited to listen to the session by visiting http://investor.bms.c...
Themefolio
Profiler
Peergroup
© BusinessWire
16.05.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant Opdivo® (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo for the treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adult patients whose tumors have PD-L1...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company.
This press release features multimedia. View the full re...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2025.
“Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. “We are advancing our multi-...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. In the Phase 3 trial, adjunctive Cobenfy treatment dem...
Themefolio
Profiler
Peergroup
© BusinessWire
18.04.2025
BMY
LISTED
NYSE
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules), simplifying treatment for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and...
Themefolio
Profiler
Peergroup
© BusinessWire
14.04.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM) did not meet its dual primary endpoints of changes from baseline to Week 48 compared to...
Themefolio
Profiler
Peergroup
© BusinessWire
11.04.2025
BMY
LISTED
NYSE
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), the most common primary liver cancer.1,2 This approval is based on the results from the...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
